55.00 7747026

TRADEMARK ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Synthesis Marketing & Communications, Inc.		09/18/2009	CORPORATION: CALIFORNIA

RECEIVING PARTY DATA

Name:	Body Sync, Inc.
Street Address:	308 1/2 S. Catalina Ave.
City:	Redondo Beach
State/Country:	CALIFORNIA
Postal Code:	90277
Entity Type:	CORPORATION: NEVADA

PROPERTY NUMBERS Total: 2

Property Type	Number	Word Mark
Serial Number:	77470266	DNA BODYSYNC
Serial Number:	77470278	BODYSYNC

CORRESPONDENCE DATA

Fax Number: (800)565-6658

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 719-475-6401

Email: docket@hollandhart.com

Correspondent Name: Jessica A. Neville
Address Line 1: P.O. Box 8749
Address Line 2: Attn: Tracy Baker

Address Line 4: Denver, COLORADO 80201-8749

ATTORNEY DOCKET NUMBER:	75182.0001
NAME OF SUBMITTER:	Jessica A. Neville
Signature:	/Jessica A. Neville/

900156386 REEL: 004161 FRAME: 0918

Date:	03/05/2010
Total Attachments: 34	
source=Assignment to Body Sync#page1.tif	
source=Assignment to Body Sync#page2.tif	
source=Assignment to Body Sync#page3.tif	
source=Assignment to Body Sync#page4.tif	
source=Assignment to Body Sync#page5.tif	
source=Assignment to Body Sync#page6.tif	
source=Assignment to Body Sync#page7.tif	
source=Assignment to Body Sync#page8.tif	
source=Assignment to Body Sync#page9.tif	
source=Assignment to Body Sync#page10.t	üf
source=Assignment to Body Sync#page11.t	üf
source=Assignment to Body Sync#page12.t	üf
source=Assignment to Body Sync#page13.t	üf
source=Assignment to Body Sync#page14.t	
source=Assignment to Body Sync#page15.t	iif
source=Assignment to Body Sync#page16.t	
source=Assignment to Body Sync#page17.t	
source=Assignment to Body Sync#page18.t	iif
source=Assignment to Body Sync#page19.t	
source=Assignment to Body Sync#page20.t	
source=Assignment to Body Sync#page21.t	üf
source=Assignment to Body Sync#page22.t	
source=Assignment to Body Sync#page23.t	if
source=Assignment to Body Sync#page24.t	
source=Assignment to Body Sync#page25.t	
source=Assignment to Body Sync#page26.t	
source=Assignment to Body Sync#page27.t	
source=Assignment to Body Sync#page28.t	
source=Assignment to Body Sync#page29.t	
source=Assignment to Body Sync#page30.t	
source=Assignment to Body Sync#page31.t	
source=Assignment to Body Sync#page32.t	
source=Assignment to Body Sync#page33.t	
source=Assignment to Body Sync#page34.t	üf

SECURED CREDITOR ASSET PURCHASE AGREEMENT

This SECURED CREDITOR ASSET PURCHASE AGREEMENT (the "Agreement") is entered into as of August 31, 2009 (the "Effective Date"), by and between SILICON VALLEY BANK, a State Chartered Bank ("Seller"), and SYNTHESIS MARKETING & COMMUNICATIONS, INC., a California corporation ("Purchaser").

RECITALS

- A. On or about August 1, 2007, Sciona, Inc., a Delaware corporation ("Borrower"), entered into a Loan and Security Agreement (as amended, the "Loan and Security Agreement") with Seller. The Loan and Security Agreement has been subsequently amended and modified. The Loan and Security Agreement together with all other documents, instruments and writings that relate to the Loan and Security Agreement are collectively referred to herein as the "Loan Documents."
- B. As security for the Loan Documents, Borrowers granted to Seller a security interest in all or substantially all of Borrowers' assets, and proceeds thereof, (the "Collateral"). Further, on or about December 12, 2008, Borrower executed an Intellectual Property Security Agreement and granted to Lender a security interest in all of Borrower's right title and interest in, to and under its intellectual property (the "Intellectual Property Collateral"). For purposes of this Agreement, the Intellectual Property Collateral shall be included in the Collateral. The Collateral is used in the operation of a CLIA certified laboratory (the "Laboratory").
- C. Lender's security interest in the Collateral is perfected by the following: (a) UCC-1 Financing Statement filed on August 2, 2007 against Borrower under File No. 20072947777 in the Office of the Delaware Secretary of State, as amended; and (b) a filing with the U.S. Patent and Trademark Office on December 31, 2008 at Reel/Frame No. 022043/0216.
- D. Borrower is in default of its obligations under the Loan Documents for failure to make payments under the Loan Documents according to their terms, among other defaults, and Seller has exercised its secured creditor rights.
- E. On June 2, 2009, Seller commenced Civil Action No. 2009CV5534 in the District Court for the City and County of Denver, State of Colorado (the "Civil Action").
- F. On June 3, 2009, the Court entered its Order Appointing Receiver, appointing Eric Grothe as Receiver over the Collateral.
- G. On July 30, 2009, Purchaser filed a Motion to Intervene in the Civil Action (the "Intervention".
- H. On August 7, 2009, Seller gave notice of private sale in accordance with CRS § 4-9-610 and, as a result of which, Seller is authorized pursuant to CRS § 4-9-617 to transfer title to the Collateral on behalf of Borrower.
- 1. Seller now desires to sell certain assets (which constitute a portion of the Collateral) to Purchaser, and Purchaser desires to purchase such assets from Seller through a private foreclosure sale under CRS § 4-9-610 on the terms and conditions set forth in this Agreement (the "Private Sale Transaction").

1

J. The parties are entering into this Agreement to effectuate the Private Sale Transaction, subject to and conditioned upon the terms set forth in this Agreement.

AGREEMENT

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledge, Purchaser and Seller hereby agree as follows:

- 1. Purchase and Sale of Transferred Assets. Seller agrees that on the Closing Date (as defined below), it shall sell to Purchaser and Purchaser agrees to purchase from Seller through a private sale under § 9-610 of the Uniform Commercial Code of Borrowers' right, title and interest in and to all of Borrower's assets, but excluding any cash, cash equivalents and licenses (the "Transferred Assets."). Notwithstanding the foregoing, the Transferred Assets shall include such licenses owned by Borrower as Purchaser shall request in writing prior to the expiration of the Due Diligence Period (defined below), provided such licenses are transferable by Seller and Purchaser would reasonably be unable to obtain equivalent licenses in Purchaser's name prior to the Closing (defined below) without such transfer (the "Licenses").
 - 2. Purchase Price; Earnest Money: Operating Expenses: Waivers.
- a. <u>Purchase Price</u>. As consideration for the sale, transfer, and conveyance of the Transferred Assets by Seller, Purchaser agrees to pay at Closing (as defined below) \$500,000.00 ("Purchase Price") for all of the Transferred Assets.
 - b. <u>Earnest Money</u>.
 - i. Purchaser shall deposit \$50,000.00 (the "Earnest Money") with a third party escrow agent ("Escrow Agent") designated by Seller and agreed to by Purchaser, in its reasonable discretion. The Earnest Money shall be deposited by Purchaser with Escrow Agent on the Effective Date of this Agreement.
 - ii. In the event that Purchaser terminates this Agreement on or before the expiration of the Due Diligence Period (as defined below) or due to a default of Seller hereunder, the Escrow Agent, or Seller if in possession of the Earnest Money, shall return the Earnest Money to Purchaser. If this Agreement is not terminated by Purchaser by the expiration of the Due Diligence Period, Escrow Agent shall deliver the Earnest Money to Seller no later than 5:00 p.m. MDT of the next business day after the expiration of the Due Diligence Period.. If the transaction contemplated herein closes, all Earnest Money shall be credited against the Purchase Price at Closing.
- c. <u>Operating Expenses</u>. Purchaser shall pay \$35,000.00 (the "Expense Payment") to Seller for use in paying the expenses associated with the operation of the Laboratory, as set forth on the budget attached hereto as Exhibit A, for the period from the Effective Date through and including the Closing Date. Purchaser shall deliver the Expense Payment to Seller according to the following schedule: (1), \$25,000.00 on September 1, 2009 and (2) \$10,000.00 no later than 5:00 p.m. MDT of the next business day after the expiration of the Due Diligence Period. The Expense Payment is non-refundable upon payment and will not be applied to the Purchase Price at Closing.

- d. <u>Escrow of Purchase Price</u>. The balance of the Purchase Price shall be deposited with the Escrow Agent no later than 5:00 p.m. MDT on the day before the Closing Date.
- Purchaser Due Diligence. Seller agrees and acknowledges that it shall provide to Purchaser all information reasonably requested by Purchaser regarding Borrower, the Transferred Assets, the Laboratory and the Facility (defined below) (collectively, the "Seller Information"), to the extent the Seller Information is in Seller's possession or reasonably available to Seller. Concurrently with the execution of this Agreement, Purchaser shall execute and deliver to Seller a Non-Disclosure Agreement with respect to the Seller Information in a form reasonably acceptable to Seller. Purchaser shall have until 5:00 p.m. MDT on the day that is fourteen (14) days after the Effective Date (the "Due Diligence Period") to review the Seller Information and to satisfy itself regarding the following:
- a. Confirmation that the Laboratory is in compliance with the Quality Assessment Plan certified for the Laboratory by CLIA;
- b. Confirmation that the intellectual property assets listed on Exhibit B hereto are not expired and are fully transferable by Seller; and
- c. Confirmation that the current version of the Rules Engine Software to be transferred to Purchaser is compliant with GAMP, or if it is not, that the assets to be transferred to Purchaser include the most recent version and the most recent GAMP compliant version of the Rules Engine Software and fully operational LIMS software.

If Purchaser is unable to confirm any of the foregoing, in Purchaser's reasonable determination, Purchaser may terminate this Agreement by delivering written notice of such election to Seller prior to the expiration of the Due Diligence Period and in such event, the Earnest Money shall be returned to Purchaser.

4. Obligations Assumed.

- a. <u>Liabilities</u>. Purchaser agrees, upon consummation of, and effective as of, the Closing, to assume those (and only those) liabilities of Seller and of Borrowers expressly listed below in this Section 4.a:
 - i. Costs and expenses associated with the ownership and operation of the Transferred Assets arising after the Closing; and
 - ii. Any applicable transfer tax as more fully described Section 12 below and in the Bill of Sale..
- b. <u>Liabilities and Obligations Not Assumed</u>. Except as expressly set forth in Section 4.a. above, Purchaser shall not assume or become obligated in any way to pay any liabilities, debts or obligations of Seller or of Borrowers whatsoever, including but not limited to any liabilities or obligations now or hereafter arising from Borrowers' business activities that took place prior to the Closing or any liabilities arising out of or connected to the liquidation and winding down of Borrowers' business.
- c. <u>No Obligations to Third Parties</u>. The execution and delivery of this Agreement shall not be deemed to confer any rights upon any person or entity other than the parties hereto, or make

any person or entity a third party beneficiary of this Agreement, or to obligate either party to any person or entity other than the parties to this Agreement. Assumption by Purchaser of any liabilities or obligations of Seller or of Borrowers under Section 4.a. above shall in no way expand the rights or remedies of third parties against Purchaser as compared to the rights and remedies such parties would have against Seller or Borrowers if the Closing were not consummated.

- d. <u>Books and Records.</u> Purchaser shall comply with all applicable federal, state and local laws and regulations with respect to any books and records of the Company that are included in the Transferred Assets and any and all confidential employee and customer information.
- 5. <u>Closing</u>. Subject to satisfaction of the conditions precedent set forth in Sections 6 and 7 below, the closing of the sale (the "Closing") will be held on the day that is five (5) days after the Expiration of the Due Diligence Period. The date on which the Closing is consummated is referred to herein as the "Closing Date."
- 6. <u>Seller's Conditions Precedent.</u> Seller's obligations to consummate the Closing shall be conditioned upon the satisfaction or waiver of the following:
- a. The representations, warranties, and covenants of Purchaser made herein shall have been true when made and at all times after the date when made, to and including the Closing Date, with the same force and effect as if made on and as of each such times, including the Closing Date.
- b. As of the Closing Date, the sale of the Transferred Assets by Seller or any of the transactions contemplated hereby are not prohibited by any stay or injunction in any litigation, governmental action, or other proceeding, including, without limitation, the "automatic stay" under 11 U.S.C. § 362 in any pending case under Title 11 of the United States Code by or against Borrowers.
- c. Purchaser shall have dismissed the Intervention with prejudice and executed and delivered to Seller a release and waiver of all claims against Seller, Borrower, Receiver and Adam Michelin, including, but not limited to, any claims of Purchaser arising from that certain Project Development Agreement dated February 2008 by and between Purchaser and Borrower, in a form reasonably acceptable to Seller.
 - d. Purchaser shall have paid the Purchase Price.
- 7. <u>Purchaser's Conditions Precedent.</u> Purchaser's obligations to consummate the Closing shall be conditioned upon the satisfaction or waiver of the following:
- a. The representations, warranties, and covenants of Seller made herein shall have been true when made and at all times after the date when made, to and including the Closing Date, with the same force and effect as if made on and as of each such times, including the Closing Date.
- b. As of the Closing Date, the sale of the Transferred Assets by Seller or any of the transactions contemplated hereby are not prohibited by any stay or injunction in any litigation, governmental action, or other proceeding, including, without limitation, the "automatic stay" under 11 U.S.C. § 362 in any pending case under Title 11 of the United States Code by or against Borrowers.
- c. Seller shall have executed and delivered to Purchaser a release and waiver of all claims against Purchaser, in a form substantially similar to that executed by Purchaser in favor Seller pursuant to Section 6.c. above.

- d. Seller shall have executed and delivered to Purchaser a Secured Party Bill of Sale in the form attached as **Exhibit C** hereto (the "Bill of Sale") with respect to the Transferred Assets.
- 8. <u>Closing Obligations</u>. At Closing, Purchaser will deliver to Seller the Purchase Price via wire transfer. Seller shall deliver to Purchaser a properly executed Bill of Sale Private UCC Sale in the form of Exhibit B attached hereto and any documentation reasonably required or requested by Purchaser to effectuate the intent of the parties to this Agreement, including documentation required by the United States or foreign patent offices (and otherwise consistent with Article 9 of the Uniform Commercial Code) necessary to implement a proper chain of title in their assignment and ownership records. Following the Closing, Purchaser will have the right to immediate possession of the Transferred Assets.
- Representations and Warranties of Seller. Except as expressly set forth in writing in this 9. Agreement, the Transferred Assets are being sold "AS IS" and "WHERE IS" with no representations or warranties of any kind, express or implied, oral or written, with respect to the physical condition, faults or value of the Transferred Assets. There is no warranty relating to title, possession, quiet enjoyment or the like in this disposition. Seller hereby expressly disclaims any and all warranties, express or implied, relating to the Transferred Assets, including without limitation, the warranty of merchantability and fitness for a particular purchase or any other fact or matter not expressly set forth herein. Upon the Closing, Purchaser shall assume all responsibility, shipping costs, storage costs, liability and obligation for the physical condition and status of the Transferred Assets. Seller makes no express or implied warranties, representations or endorsements whatsoever, including, without limitation, warranties of merchantability, non-infringement or fitness for a particular purpose with regard to the Transferred Assets, and Seller hereby expressly disclaims any such warranties to the maximum extent permitted by applicable law. Seller makes no representation or warranty and have no liability whatsoever on behalf of Seller or any third parties with regard to the operation, performance, nonperformance, quality, availability, completeness, accuracy or security any of the Transferred Assets or the delay, error, or interruption of the flow of information in connection with use of any of the foregoing. Seller has not undertaken any independent investigation (nor does Seller intend to do so) and Seller disclaims any liability as a result of or obligation to do so, to determine if there is any pending, threatened or potential inquiry, claim, investigation, litigation, proceeding or decree by any federal, state or local authority, or administrative agency, or any private party against or relating to the Transferred Assets, or if the Transferred Assets infringe any third party's intellectual property rights. Purchaser is sophisticated with respect to the Transferred Assets, and in fact, have more knowledge of, and familiarity with, the Transferred Assets than Seller (who merely foreclosed on a security interest in the Transferred Assets). Notwithstanding the foregoing, Seller represents and warrants to Purchaser, as follows:
- a. Seller (i) is a corporation duly organized, validly existing, and in good standing under the laws of its jurisdiction of incorporation; (ii) has all requisite corporate power and authority to execute, deliver, and perform the transactions contemplated hereby; and (iii) is duly qualified or authorized to conduct business and is in good standing as a foreign corporation in such jurisdictions where failure to be so qualified or authorized could reasonably be expected to have a Material Adverse Effect on Seller. For purposes of the Agreement, a "Material Adverse Effect" shall mean a material adverse effect on the enforceability of the Agreement.
- b. The execution, delivery, and performance by Seller of this Agreement and the consummation of the transaction contemplated hereby are within the power of Seller and have been duly authorized by all necessary actions on the part of Seller. The execution of this Agreement by Seller constitutes, or will constitute, a legal valid and binding obligation of Seller, enforceable against Seller in accordance with its terms, except as limited by bankruptcy, insolvency, or other laws of general application relating to or affecting the enforcement of creditors' rights generally and general principles of equity.

d. Borrower is in default of its obligations under the Loan Documents and other obligations owing to Seller and Seller has validly exercised its rights under the Loan Documents and applicable law in foreclosing on the Collateral and Transferred Assets.

effect.

- e. Seller placed Notices of Private Sale Under Uniform Commercial Code, in the forms previously provided to Purchaser, in the United States Mail, first class, postage prepaid, addressed to those persons on the mailing list attached to said Notices on August 7, 2009.
- 10. <u>Representations and Warranties of Purchaser</u>. Purchaser represents and warrants to Seller, as follows:
- a. Purchaser (i) is duly organized corporation, validly existing, and in good standing under the laws of the State of California; and (ii) has all requisite corporate power and authority to execute, deliver, and perform the transactions contemplated hereby.
- b. The execution, delivery, and performance by Purchaser of this Agreement and the consummation of the transaction contemplated hereby are within the power of Purchaser and have been duly authorized by all necessary actions on the part of Purchaser. The execution of this Agreement by Purchaser constitutes, or will constitute, a legal valid and binding obligation of Purchaser, enforceable against Purchaser in accordance with its terms, except as limited by bankruptcy, insolvency, or other laws of general application relating to or affecting the enforcement of creditors' right generally and general principles of equity.
- c. No consent, approval, authorization or order of, or registration or filing with, or notice to, any court or governmental agency or body having jurisdiction or regulatory authority over Purchaser (or any of its properties) is required for (i) Purchaser's execution and delivery of this Agreement (and each agreement executed and delivered by it in connection herewith) or (ii) the consummation by Purchaser of the transactions contemplated by this Agreement (and each agreement executed and delivered by it in connection herewith) or, to the extent so required, such consent, approval, authorization, order, registration, filing or notice has been obtained, made or given (as applicable) and is still in full force and effect.
- d. No person or entity acting on behalf of Purchaser or Seller or any of its affiliates or under the authority of any of them, except Peter Vitulli and Rosalynn Gill, is or will be entitled to any brokers or "finders" fee or any other commission or similar fee, directly or indirectly, from Purchaser or any of its affiliates in connection with any of the transactions contemplated hereby. Seller shall be responsible for paying any commission and/or fees due to Peter Vitulli and Rosalynn Gill with respect to the transactions contemplated hereby.
- 11. <u>Expenses</u>. Except as provided in the next sentence or as otherwise provided in this Agreement, Purchaser and Seller shall each bear their own expenses incurred in connection with the

transactions contemplated by this Agreement. Notwithstanding the foregoing, if either party breaches this Agreement, the breaching party shall be responsible for the costs and expenses, including reasonable attorneys' fees, incurred by the other party in enforcing this Agreement against such breaching party by the non-breaching party.

- 12. <u>Transfer Taxes</u>. Purchaser shall pay all sales, use, excise, stamp, documentary, filing, recording, transfer or similar fees or taxes or governmental charges, as levied by any taxing authority or governmental agency in connection with the transfer of Transferred Assets contemplated by this Agreement. Prior to the Closing Date, (i) Purchaser shall deliver to Seller evidence that these transactions are exempt from sales tax, or (ii) Purchaser shall remit to Seller any sales tax due as a result of these transactions. Seller hereby agrees to file all necessary documents with respect to such amounts in a timely manner.
- 13. <u>Facility Lease; Post-Closing Occupancy and Employees; Continuing Access to Books</u> and Records; Licenses.
- a. Seller shall pay rent for the month of September for the space in which the Laboratory is currently operated, which is located at 12635 E. Montview Blvd., Suite 217, Aurora, CO 80045 (the "Facility"). Seller will notify the landlord of the Facility that Receiver shall abandon the Facility on or before the Closing Date. Purchaser shall be solely responsible for negotiating a new lease with said landlord or otherwise vacating the Facility and removing the Transferred Assets therefrom after the Closing. The Closing is not contingent on Purchaser obtaining a lease for the Facility.
- b. Purchaser is solely responsible for employing former Borrower employees and the Closing under this Agreement is not contingent on any such employment.
- c. Purchaser shall permit Seller and Borrower access and use of any of Borrower's books and records that are included in the Transferred Assets for wind down and similar corporate purposes that do not compete with Purchaser following the Closing Date for a period of 18 months. Such access and use shall be permitted during normal business hours and shall be conducted to minimize disruption to Purchaser's post-closing operations.
- d. Purchaser acknowledges and agrees that other than the Licenses, Purchaser shall be responsible for obtaining all other licenses and permits it requires in order to consummate the transactions contemplated herein and to use the Transferred Assets, Facility and Laboratory after the Closing, including, but not limited to, those licenses and/or permits required or desirable for it to (i) own and use the Transferred Assets, (ii) use and occupy the Facility, (iii) conduct business in the jurisdictions in which the Transferred Assets and Facility are located, (iv) operate the Laboratory, and (v) employ workers to operate the Laboratory.
- 14. <u>Indemnity</u>. Purchaser hereby agrees to indemnify, defend and hold Seller, Receiver and Borrowers harmless from and against, any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, proceedings, costs expenses and disbursements of any kind or nature whatsoever (including, without limitation, all reasonable costs and expenses of attorneys) which may be imposed on, incurred by, or asserted against Seller, Receiver or Borrowers, as the case may be, in any way relating to or arising out of, or alleged to relate or arise out of, any action or inaction on the part of Purchaser in connection with the Books and Records or any other confidential employee or customer information or other breach of this Agreement.
- 15. <u>Notices</u>. Any notice or other communication provided for herein or given hereunder to a party hereto shall be in writing, and shall be deemed given when personally delivered to a party set forth

below or when sent by telecopy providing a transmission confirmation (provided that such notice is immediately sent by a recognized overnight delivery service), or three(3) days after mailed by first class mail, registered, or certified, return receipt requested, postage prepaid, or when delivered by nationally-recognized overnight delivery service, with proof of delivery, delivery charges prepaid, in any case addressed as follows.

To Seller:

Silicon Valley Bank ATTN: C. Diane LeMay 38 Technology Drive, Suite 150 Irvine, CA 92618 Telephone: 949.754.0815 Facsimile: 949.790.9026 dlemay@svbank.com

with a copy to:

Duncan E. Barber, Esq.
Bieging Shapiro & Burrus LLP
4582 South Ulster Street Parkway
Suite 1650
Denver, CO 80237
Telephone: (720) 488-0220
Facsimile: (720) 488-7711
dbarber@bsblawyers.com

To Purchaser:
Synthesis Marketing & Communications, Inc.
ATTN: Vincent Pavelock
308.5 S. Catalina Ave.
Redondo Beach, CA 90277
Telephone: (310) 376-8093
Facsimile:
Email: vp@synthink.com

with a copy to:
Mark B. Simpkins, Esq.
11 Golden Shore
Suite 430
Long Beach, CA 90802
Telephone: (562)436-9631
Facsimile: (562)436-1467
Email: mark_simpkins@hotmail.com

16. Miscellaneous.

- a. <u>Entire Agreement</u>. This Agreement, together with the schedules and exhibits attached hereto, constitutes the entire agreement of the parties hereto regarding the purchase and sale of the Transferred Assets, and all prior agreements, understandings, representations and statements, oral or written, are superseded hereby.
- b. <u>Captions</u>. Section captions used in this Agreement are for convenience only, and do not affect the construction of this Agreement.
- c. <u>Counterpart Execution</u>. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which shall together constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this Agreement by facsimile transmission shall be effective as delivery of a manually executed counterpart thereof and shall be deemed an original signature for all purposes.
- d. <u>Severability</u>. If any provision of this Agreement shall for any reason be held to be invalid or unenforceable, such invalidity or unenforceability shall not affect any other provision of this Agreement, but this Agreement shall be construed as if such invalid or unenforceable provision had never been contained in this Agreement.
- e. <u>Further Assurances</u>. At any time or from time to time after the Closing, without further consideration, Seller shall, at the request of Purchaser, execute and deliver such further instruments and document as Purchaser may reasonably request as may be reasonably necessary to evidence or effect the consummation of the transactions contemplated by this Agreement.
- f. Amendments and Waivers. No amendment of any provision of this Agreement shall be valid unless the same shall be in writing and signed by Purchaser and Seller. No waiver by any party hereto of any default, misrepresentation, or breach of warranty or covenant hereunder, whether intentional or not, shall be deemed to extend to any prior or subsequent default, misrepresentation, or breach of warranty or covenant hereunder or affect in any way any rights arising by virtue of any prior or subsequent such occurrence.
- g. <u>Governing Law</u>. This Agreement shall be governed by and interpreted in accordance with the internal laws of the State of Colorado (without reference to conflicts of law principles).
- h. Waiver of Trial by Jury. SELLER AND PURCHASER HEREBY EXPRESSLY WAIVE ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION, CAUSE OF ACTION, OR PROCEEDING ARISING UNDER OR WITH RESPECT TO THIS AGREEMENT, OR IN ANY WAY CONNECTED WITH, OR RELATED TO, OR INCIDENTAL TO, THE DEALINGS OF THE PARTIES HERETO WITH RESPECT TO THIS AGREEMENT OR THE TRANSACTIONS RELATED HERETO OR THERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND IRRESPECTIVE OF WHETHER SOUNDING IN CONTRACT, TORT, OR OTHERWISE. SELLER AND PURCHASER HEREBY AGREE THAT ANY SUCH CLAIM, DEMAND, ACTION, CAUSE OF ACTION, OR PROCEEDING SHALL BE DECIDED BY A COURT TRIAL WITHOUT A JURY AND THAT ANY PARTY HERETO MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE OTHER PARTY OR PARTIES HERETO TO WAIVER OF ITS OR THEIR RIGHT TO TRIAL BY JURY.

- Submission to Jurisdiction; Selection of Forum. EACH PARTY HERETO (A) AGREES THAT IT SHALL BRING ANY ACTION OR PROCEEDING IN RESPECT OF ANY CLAIM ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTAINED IN OR CONTEMPLATED BY THIS AGREEMENT, WHETHER IN TORT OR CONTRACT OR AT LAW OR IN EQUITY, EXCLUSIVELY IN (I) THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLORADO OR IN THE EVENT THAT SUCH COURT LACKS SUBJECT MATTER JURISDICTION OVER THE ACTION OR PROCEEDING, (II) IN AN APPROPRIATE STATE COURT LOCATED IN EL PASO COUNTY, COLORADO IS HÉREAFTER REFERRED TO AS THE "CHOSEN COURT") AND (B) IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE CHOSEN COURT, (C) WAIVES, TO THE EXTENT PERMITTED BY APPLICABLE LAW, ANY OBJECTION TO LAYING VENUE IN ANY SUCH ACTION OR PROCEEDING IN THE CHOSEN COURT, (D) WAIVES ANY ARGUMENT THAT THE CHOSEN COURT IS AN INCONVENIENT FORUM OR DOES NOT HAVE JURISDICTION OVER ANY PARTY THERETO, AND (E) AGREES THAT SERVICE OR PROCESS UPON ANY PARTY IN ANY SUCH ACTION OR PROCEEDING SHALL BE EFFECTIVE IF NOTICE IS GIVEN IN ACCORDANCE WITH SECTION 15 OF THIS AGREEMENT.
- j. <u>Construction</u>. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement. Any reference to any federal, state, local, or foreign statute or law shall be deemed also to refer to all rules and regulations promulgated thereunder, unless the context requires otherwise. The word "including" shall mean "including without limitation".
- k. <u>No Third-Party Beneficiaries</u>. This Agreement shall not confer any rights or remedies upon any person or entity other than the parties hereto and their respective successors and permitted assigns.
- l. <u>Successor and Assigns</u>. This Agreement shall be binding upon and inure to the benefit of the parties named herein and their respective successors and permitted assigns. Neither party may assign its rights or interests hereunder without providing the other party with prior written notice; provided, however, that Purchaser shall be entitled to assign its rights under this agreement to an entity wholly-owned by it. Neither party may delegate all or any of its obligations or duties hereunder, without the prior written consent of the other party.
- m. <u>Fees and Expenses</u>. Seller and Purchaser shall each bear their own expenses, including but not limited to legal fees, incident to the negotiation and preparation of this Agreement and the consummation of the transactions contemplated hereby.
- n. <u>Confidentiality</u>. Purchaser and Seller agree that they will hold in confidence all information, data and documents obtained by them or any of their representatives from any representative, officer or employee of each other, and that none of them nor any of their representatives will disclose any such information, data or documents to any third party and none of them will discuss this Agreement or the transactions contemplated hereby with any party other than officers, employees, agents and representatives of the party or their legal counsel and financing sources deemed necessary to the completion of the transactions described herein.
- o. <u>Survival</u>. The parties' representations, warranties and obligations contained in this Agreement shall survive the Closing.

IN WITNESS WHEREOF, Purchaser and Seller have caused this Agreement to be executed as of the day and year first above written.

SELLER:

SILICON VALLEY BANK, a State Chartered Bank Pursuant to CRS § 9-617 For itself and for and on behalf of Sciona, Inc. a Delaware corporation

By: Name: Sheila Colson
Its: Advisor

PURCHASER:

SYNTHESIS MARKETING & COMMUNICATIONS, INC., a California corporation

IN WITNESS WHEREOF, Purchaser and Soller have caused this Agreement to be executed as of the day and year first above written.

SELLER:

SILICON VALLEY BANK, a State Chartered Bank Pursuant to CRS § 9-617 For itself and for and on behalf of Sciona, Inc. a Delaware corporation

By: Name: Sheila Colson Its: Advisor

PURCHASER:

SYNTHESIS MARKETING & COMMUNICATIONS, INC., a California corporation

By: Attlich Chaniely Namo: Patricis Ekonnedy Its: IN WITNESS WHEREOF, Purchaser and Soller have caused this Agreement to be executed as of the day and year first above written.

SELLER:

SILICON VALLEY BANK, a State Chartered Bank Pursuant to CRS § 9-617 For itself and for and on behalf of Sciona, Inc. a Delaware corporation

PURCHASER:

SYNTHESIS MARKETING
COMMUNICATIONS, INC., a California corporation

By: Stillica Clemely
Namo Patricia E Koonedy
His:

EXHIBIT A

CONTROL DE PROPERTO DE LA CONTROL DE LA CONT

LABORATORY BUDGET

(See Attached)

Sciona, Inc. September 2009 Operating Expense Budget

Business Exit Strategies	Contractor services	\$5,000.00
FedEx	Shipping	218.22
Fitzsimons Redevelopment Authority	Rent	10,431.36
Ikon Financial Services	Copier	1,412.32
IP5280	Phones	1,885.33
Michael Bauer MD & Associates Inc	Certification Expense	5,000.00
MX Logic	E-Mail	137.50
RackSpace Managed Hosting	Web Hosting	765.00
Several Payees	Payroll	22,826.68
Total		\$47,676.41

EXHIBIT B

INTELLECTUAL PROPERTY

(See Attached)

Registration/ Application Date

Registration/ Application Number

Page 1 of 1

Description Not Applicable

Page 1 of 5

		nethod	ized	S.1			sed on		food									, 19 gene					נט	aims	veg and	•
Key Claims	5/30/2006 Business model	A computer assisted method	for providing personalized	lifestyle advice plan	comprising:	-risk based alleies	-recommendations based on	risk factors	-including max or min food	suptypes ""		un	ıın	III	Additional Claims TBD		Case I plus delivery of	personalized products, 19 gene	panel described	Provisional filing		GSTP1 variations and	prescribing weight loss	program, additional claims	related to cruciferous veg and	•
Date issued	5/30/2006									70001 0013	0/22/2001	pending	pending	pending	pending		pending							•		
Country	USA									A.: +:	Australia	Japan	Europe	Canada	USA		USA			USA						
Reference Number			,	~ *****						A 418 / CD 61 67 37 7 E	בארדה ווא ווא ווא	AHB/FP6162309	AHB/FP6162333	AHB/FP6162317	AHB/FP6370118		NRS/FP6351183		•	5588-12PROV	AHB/FP6349179					
Title	Computer Assisted Means for Assessing Lifestyle Risk Factors									HI.		477	un	un	Case I divisional		Computer Assisted Means for Providing	Personalized Healthcare Products		Methods for Determining Gene-Nutrient	Interactions					•
Application Number										2002276590		2002-561755	02716200.7	2435682	11/277,525	20060178837		20080275912		61,077,850						
Patent Number	7,054,758						Contract																			

Control of the Contro

Patents

Page 2 of 5

weight loss program, additional Additional claims related to kit, 3/25/2003 Detecting FPGS gene variations claims for individuals over the ILG variations and prescribing variations in the MTHFR gene Identify risk of bone fracture treatment regimes to reduce treatment for patients based 12/16/2003 Detecting TS gene variations pharmacological treatment associated with Estrogen Receptor + VDR genetic Determining method of on detection of 1 or 2 Key Claims risk – diet, exercise, Provisional filing: age of 50 Date issued 4/8/2008 6/20/08 pending pending Filed Country USA USA USA USA USA USA Reference Number AHB/FP6349161 588-11PROV 5588-6-1 5588-8-2 5588-8-3 Gene Sequence Variances in Genes Related | 5588-1-1 Oxagen Oxagen 5588-6 Nuvelo Nűvelő Variances Having Utility in Determining the Nuvelo OX43 Varil Methods for Determining Gene-Nutrient Predictive of Increased Susceptibility to Determining the Treatment of Disease Thymidylate Synthase Gene Sequence to Folate Metabolism Having Utility in Determining the Treatment of Disease Folylpolyglutamate Synthetase Gene Sequence Variances Having Utility in Estrogen Receptor Alleles That Are Title Treatment of Disease **Bone Fracture** nteractions 20050202435 Application 20050191691 Number 10/601,345 61,077,016 12,062,338 09/962,665 09/963,333 11/100,921 Serial Serial Serial 7,354,712 6,537,759 6,664,062 Number Patent

Patents

Patent	Application					
Number	Number	Title	Reference Number	Country	Date issued	Key Claims
6,803,197	09/796,991		5588-2	USA	10/12/2004	10/12/2004 Risk assessment based on VDR
		Bone Damage by Screening Polymorphisms OX-06	90-XO			and/or Col1A1 sequence
		in the Vitamin D Receptor Gene	Oxagen			variations, with Calcium and
						blood measures claimed
						בסמוונפו זו גם סכוווואו
		99947490.9	AHB/FP6372916	Ē	pending	
	2000-570366		AHB/FP6373179	JP	pending	
6,808,881	09/786,992	Method for Determining Susceptibility to	5588-3	USA	10/26/2004	10/26/2004 Risk based on VDR sequence
		Heart Disease by Screening Polymorphisms OX-07	OX-07		•	variations and calcium above
		in the Vitamin D Receptor Gene	Oxagen			1302 mg/day
Pending		99947491.9	AHB/FP6372932	ΕP	Granted 9/12/08	
			AHB/FP6373120	dſ	pending	
	10/703,715	Divisional	5588-3-1	USA	Pending	Further claims related to
	20050074786		Oxagen			treatment, calcium
						measurements and heart
						damage measures in males
		ising a Genetic	5588-7	USA	Pending	Detection of variations in the
	20060211/4	Susceptibility for Bone Damage	0X44			INHBA (inhibin beta-A gene) to
			Cxageil			predict susceptibility to bone
					•	damage
	·	2004234611	AHB/FP6373161	AU	pending	
		2528143	AHB/FP6373153	CA	pending	
		514.4	AHB/FP6373146	CN	pending	
_		04730309.4	АНВ/FP6373013	EP	pending	

Page 3 of 5

Number	Application Number	Title	Reference Number	Country	Date issued	Kev Claims
	10/270,714	Susceptibility to Bone Damage	5588-4	1154	Danding	Detection of variations in
(1.4.)	20030165928		OX22	5	יכוותוומ	METHER and Cold to prodict
						יאויוורוא פווח כמידעד גם חופחורו
			Oxagen			susceptibility to bone damage,
			***************************************			measurement of
*****						homocysteine, treatment with
						folicacid
Pending	KS-13-010	A Method of Determining Susceptibility to	AHB/FP6373138	JP.	Granted	m
		Bone Damage	0X22		8/22/2008	
6,759,200	09/962,677	Thymidine Phosphorylase Gene Sequence	5588-8-4	USA	7/6/2004	Detection of variations in the
		Variances Having Utility in Determining the Oxagen	Óxagen			thymidine phosphorylase
		Treatment of Disease	:			genes
99051168	2004201470	Gene Sequence Variances With Utility In	639050R	AU		Detection of Folate pathway
51168/99	1999051168	Determining The Treatment Of Disease	Vari1			gene variations
			Nuvelo			3
768810		an	Vari1	AU	3/16/2007	3/16/2007 Detection of Thymidylate
**********			AHB/FP6390587			synthase variations
			Nuvelo			
		on Susceptibility to	SPH/FP6335905	SN	pending	Exclusive license with
	20060246454	Treatment with Fish Oil	Soton		- ·	University of Southampton
						IL6 or TNFa variations and
						treatment with Fish oil/Omega
			•			3 to reduce rytokine
						production
		•				*Sciona pays for patent
						prosecution as per the
	0 0070070					licensing agreement
	04/20000.0		SPH/FP6335723	EP	pending	

Page 4 of 5

Page 5 of 5

notice of allowance expected Key Claims 7/15/2008 Granted Date issued paperwork submitted 8/28/08 Final Country 로 일 음 물 Reference Number SPH/FP6335707 SPH/FP6335715 SPH/FP6335699 Title 200480016679.8 Application 2006-506160 Number 2004233299 2523377 Number Pending Patent

Patents

R
Class
O10 Prepackaged, in-home nutrigenetic analysis kit comprised of a swab, Section 8 & 15 Affidavit of instructional panel, container for the swab and pre-paid envelope for due between obtaining and archiving an oral swab specimen of an individual's DNA 05-01-2012 & 05-01-2013 to be used to identify lifestyle recommendations based upon the individual's genetic profile, sold with a questionnaire detailing nutrition and lifestyle habits (10-31-2003)
Biochemistry research services; biological development services, namely, human genetic profiling to establish nutrition and lifestyle analysis and recommendation; biological research services; biotechnological research in the fields of nutrition and health care; biotechnology research; biotechnology testing; collection of data derived from clinical trials in the fields of genetics, nutrition, lifestyle and health care; compliation of scientific information in the fields of genetics, nutrition, lifestyle and healthcare; consultancy services relating to food; preparation of reports relating to scientific research; research services, namely, human genetic profiling to establish nutrition and lifestyle analysis and recommendations; and provision of scientific information, namely, human genetic profiling to establish nutrition and lifestyle analysis and recommendations (10-31-2003)
O44 Advisory services, namely, advisory services relating to diet; advisory services relating to health; advisory services relating to nutrition; consultancy services relating to nutrition; consultancy services relating to nutrition; denetic profiling to nutrition; genetic testing, namely, human genetic profiling to establish nutrition and lifestyle analysis and recommendations; professional consultancy relating to health and professional consultancy relating to health care (10-31-2003)

Page 1 of 6

	Remarks			
Upcoming Action Item	(Pending Items in bold)	Section 8 & 15 Affidavit of use due between 10-23-2012 & 10-23-2013	Renewal due between 10-23-2016 & 10-23-2017	
Goods/Services	(date of first use)	Prepackaged, in-home nutrigenetic analysis kit comprised of a swab, section 8 & 15 Affidavit o instructional panel, container forth swab and pre-paid envelope for due between obtaining and archiving an oral swab specimen of an individual's DNA 10-23-2012 & 10-23-2013 to be used to identify lifestyle recommendations based upon the individual's genetic profile, sold with a questionnaire detailing nutrition and lifestyle habits (02-28-2003)	Biochemistry research services; biological development services; namely, human genetic profiling to establish nutrition and lifestyle analysis and recommendations; biological research services; biotechnological research in the fields of nutrition and health care; biotechnology research; biotechnology testing; collection of data derived from clinical trials in the fields of genetics, nutrition, lifestyle and health care; compilation of scientific information in the fields of genetics, nutrition, lifestyle and health care; consultancy services relating to food; preparation of reports relating to scientific research; research relating to molecular sciences; genetic profiling to establish nutrition and lifestyle analysis and recommendations; and provision of scientific information, namely, human genetic profiling to establish nutrition and lifestyle analysis and recommendations (-28-2003) nutrition and lifestyle analysis and recommendations (-28-2003)	Advisory services, namely, advisory services relating to diet; advisory services relating to health; advisory-services relating to nutrition; consultancy services relating to nutrition; consultancy services relating to nutrition; counseling relating to nutrition; genetic testing, namely, human genetic profiling to establish nutrition and lifestyle analysis and recommendations; professional consultancy relating to health and professional consultancy relating to health care (02-28-2003)
	Class	500	042	044
Reg. &	Serial No.	76/635,309 Filed 04-07-2005	3,319,058 Registered 10-23-2007	
Mark	H&H Reference	THE SCIENCE OF 76/635,309 YOU 04-07-2005	51757.0005	

Page 2 of 6

Classs (date of first use) 042 Biochemistry research services; biological development services, namely, human genetic profiling to establish nutrition and lifestyle analysis and recommendation; highorical recognitions and recommendation; highorical recognitions.	Serial No. Class 76/635,306 042 Biocher Filed namely 04-07-2005 analysis
blotechnological research in the fields of nutrition and health care; biotechnology research; biotechnology testing; collection of data derived from clinical trials in the fields of genetics, nutrition, lifestyle and health care; compilation of scientific information in the fields of genetics, nutrition, lifestyle and healthcare; consultancy services relating to food; preparation of reports relating to scientific research; research relating to molecular sciences; genetics research; provision	<u> </u>
or research services, namely, human genetic profiling to establish nutrition and lifestyle analysis and recommendations; and provision of scientific information , namely, human genetic profiling to establish nutrition and lifestyle analysis and recommendations (08-31-2004) 2004) O44 Advisory services, namely, advisory services relating to diet; advisory Renewal due between confine relating to halify.	
services relating to health; advisory services relating to nutrition; consultancy services relating to nutrition; consultancy services relating to nutrition; genetic testing, namely, human genetic profiling to establish nutrition and lifestyle analysis and recommendations; professional consultancy relating to health and professional consultancy relating to health care (08-31-2004)	
Utul Prepackaged, in-home, personal genetic analysis set for in-home use comprised of a blood sample collection tool, cheek swab, and/or saliva sample, container and envelope for obtaining and archiving a DNA specimen, all sold as a unit with a questionnaire detailing nutrition and lifestyle habits and instructions therefore, used to provide lifestyle recommendations based on an individual's nutritional and lifestyle information (07-01-2007)	70/04/25/359 010/04/26/25/25/35/35/35/35/35/35/35/35/35/35/35/35/35

Page 3 of 6

			_		
Remarks		Published for Opposition 11-25- 2008			
Upcoming Action Item (Pending Items in bold)	Renewal due between 09-16-2017 & 09-16-2018			Pending Publication	
Goods/Services (date of first use)		009 Computer program used to identify lifestyle recommendations based upon Individual genetic profile data and lifestyle questionnaire data		O10 Prepackaged, in-home, personal genetic analysis set for in-home use Pending Publication comprised of a blood sample collection tool, cheek swab, and/or saliva sample, container and envelope for obtaining and archiving a DNA specimen, all sold as a unit with a questionnaire detailing nutrition and lifestyle habits and instructions therefore, used to provide lifestyle recommendations based on an individual's nutritional and lifestyle information	016 Printed publications, namely, articles and newsletters on the topic of nutrition, fitness and lifestyle 044 Nutritional consulting services, weight management and fitness consulting services
Class		600		010	016
Reg. & Serial No.	3,500,556 Registered 09-16-2008	77/470,228 Filed 05-09-2008		77/470,266 Filed 05-09-2008	
Mark H&H Reference	51757.0008	GENOSTIC RULES ENGINE	51757.0011	DINA BODYSYNC 77/470,266 Filed 05-09-2008	51757.0012

Page 4 of 6

Remarks (Pending Items in bold) Upcoming Action Item Pending Publication 016 Printed publications, namely, articles and newsletters on the topic of 010 Prepackaged, in-home, personal genetic analysis set for in-home use saliva sample, container and envelope for obtaining and archiving a comprised of a blood sample collection tool, cheek swab, and/or nutrition and lifestyle habits and instructions therefore, used to 044 Nutritional consulting services, weight management and fitness DNA specimen, all sold as a unit with a questionnaire detailing provide lifestyle recommendations based on an individual's 005 Nutritional Supplements and meal replacement shakes (date of first use) Goods/Services nutritional and lifestyle information nutrition, fitness and lifestyle consulting services Class Serial No. Reg. & 77/470,278 05-09-2008 Fled H&H Reference Mark BODYSYNC 51757.0013

Trademarks

Page 5 of 6

Mark	Reg. &		Goods/Services	Hacoming Action 15cm	
H&H Reference	Serial No.	Class		(Pending Items in hold)	Ramarke
OPTIMAL	76/635,308	044	044 Blochemistry research services; biological development services.	ARANDONED	Coilura ta Ala
HFALTH	Filed	-1	<u>e</u>	04-14-2007	Statement of I to
THROUGH	04-07-2005				
GENETICS			biotechnology research; blotechnology testing; collection of data		
			and health care; compilation of scientific information in the fields of		
			genetics, nutrition, lifestyle and health care; preparation of reports relating to scientific research; research relating to molecular sciences:		
			genetics research; provision of research services; namely, human		
			recommendations; and provision of scientific information, namely,		
			human genetic profiling to establish nutrition and lifestyle analysis and recommendations		
51757.0007		042	042 Advisory services namely advisory congres volution to distance advisory		
			services relating to health; advisory services relating to nutrition;		
			consultancy services relating to nutrition; food nutrition consultation; counseling relating to nutrition; genetic testing, namely, human		···
			genetic profiling to establish nutrition and lifestyle analysis and		
			professional consultancy relating to health care		
	76/635,329 cilod	600	uter program used to identify lifestyle recommendations based	ABANDONED	Failure to file
RULES ENGINE	04-07-2005		upon individual genetic profile data and lifestyle questionnaire data	10-05-2007	Statement of Use
51757 0003					

Page 6 of 6

EXHIBIT C

BILL OF SALE

(See Attached)

BILL OF SALE PRIVATE UCC SALE

THIS BILL OF SALE PRIVATE UCC SALE (the "Bill of Sale"), dated as of ______, 2009, is by and between SILICON VALLEY BANK, a State Chartered Bank ("Seller"), as authorized pursuant to Colorado Revised Statute § 4-9-617, on behalf of Sciona, Inc. a Delaware corporation (the "Debtor") and SYNTHESIS MARKETING & COMMUNICATIONS, INC., a California corporation ("Buyer").

Recitals

- A. Seller and Buyer are parties to that certain Secured Creditor Asset Purchase Agreement dated August 31, 2009 (the "Purchase Agreement"). Capitalized terms used in this Bill of Sale and defined in the Purchase Agreement shall have the meanings set forth in the Purchase Agreement unless otherwise defined herein.
- B. Under the Purchase Agreement, Seller agreed to sell and Buyer agreed to buy the Transferred Assets, as more fully described in the Purchase Agreement (the "Assets").
- C. Seller has exercised its post-default remedies with respect to the Assets and has noticed the sale of the Assets to Buyer by private UCC sale in accordance with C.R.S. § 4-9-610 of the Uniform Commercial Code (the "UCC Foreclosure Sale").
- D. In accordance with C.R.S. § 4-9-617, Seller and Buyer now desire to confirm the conveyance of all of Debtor's rights, title and interest in and to the Assets to Buyer as a result of the UCC Foreclosure Sale.

Agreements

NOW THEREFORE, for Five Hundred Thousand and 00/100 Dollars (\$500,000.00), and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Seller, for itself and for and on behalf of Debtor, hereby sells, conveys, transfers and assigns unto Buyer, its successors and assigns, all of Debtor's interest in the Assets.

SELLER MAKES NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, AS TO ANY MATTER WHATSOEVER, INCLUDING, BUT NOT LIMITED TO: THE TITLE TO THE ASSETS; THE CONDITION, DESIGN, OR QUALITY OF THE ASSETS; THE FITNESS OF THE ASSETS FOR USE OR FOR A PARTICULAR PURPOSE; THE MERCHANTABILITY OF THE ASSETS; COMPLIANCE OF THE ASSETS WITH THE REQUIREMENTS OF ANY LAWS, RULES, SPECIFICATIONS OR CONTRACTS PERTAINING THERETO; PATENT INFRINGEMENT; LATENT DEFECTS: THE QUALITY OF THE MATERIAL OR WORKMANSHIP OF THE ASSETS OR THE CONFORMITY OF THE ASSETS TO THE PROVISIONS AND SPECIFICATIONS OF ANY PURCHASE ORDER RELATING THERETO; THE OPERATION, USE, OR PERFORMANCE OF THE ASSETS; OR ANY OTHER REPRESENTATION OR WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, WITH RESPECT TO THE ASSETS. BUYER ALSO ACKNOWLEDGES THAT SELLER HAS MADE NO REPRESENTATION OR WARRANTY OF ANY KIND, NATURE OR DESCRIPTION, EXPRESS OR IMPLIED, WITH RESPECT TO THE OPERATION, USE OR PERFORMANCE OF THE ASSETS.

SELLER SHALL HAVE NO LIABILITY TO BUYER OR ANY PERSON WHOMSOEVER (INCLUDING LESSEES OR PURCHASERS OF ALL OR ANY OF THE ASSETS) FOR ANY CLAIM, LOSS, DAMAGE OR EXPENSE (INCLUDING ATTORNEYS FEES) OF ANY KIND OR NATURE, WHETHER SPECIAL, CONSEQUENTIAL, ECONOMIC OR OTHERWISE, CAUSED OR ALLEGED TO BE CAUSED DIRECTLY, INDIRECTLY, INCIDENTALLY, OR CONSEQUENTIALLY BY THE ASSETS OR ANY PART THEREOF OR PRODUCTS THEREFROM, BY ANY INADEQUACY OF THE ASSETS OR DEFECT OR DEFICIENCY THEREIN, BY ANY INCIDENT WHATSOEVER ARISING IN STRICT LIABILITY OR OTHERWISE FROM SELLER'S OR BUYER'S NEGLIGENCE OR OTHERWISE, OR FOR ANY LOSS OF BUSINESS OR DAMAGE WHATSOEVER AND HOWSOEVER CAUSED, OR ARISING OUT THE ASSETS.

Buyer acknowledges that Seller has made no representation or warranty concerning the location of the Assets nor whether all of the Assets are in existence or operational. BUYER PURCHASES THE ASSETS "AS IS" AND WHERESOEVER LOCATED, WITHOUT REPRESENTATION OR WARRANTY OF ANY KIND. Buyer accepts the Assets subject to the terms of this Bill of Sale, and subject to the terms, conditions, and warranties contained in the Purchase Agreement.

Buyer agrees to be responsible for all taxes, that are now existing or hereafter are incurred, assessed, or imposed on the Assets or as a result of the ownership or sale of the Assets. Buyer hereby agrees to hold Seller harmless from and against any and all taxes that are now existing or are hereafter incurred, assessed or imposed on the Assets or as a result of the ownership of the Assets.

SELLER:	BUYER:
SILICON VALLEY BANK, a State Chartered Bank Pursuant to § 9-617 For itself and for and on behalf of Sciona, Inc. a Delaware corporation	SYNTHESIS MARKETING & COMMUNICATIONS, INC., a California corporation
By: Name: Title:	By: Name: Title:

SELLER SHALL HAVE NO LIABILITY TO BUYER OR ANY PERSON WHOMSOEVER (INCLUDING LESSEES OR PURCHASERS OF ALL OR ANY OF THE ASSETS) FOR ANY CLAIM, LOSS, DAMAGE OR EXPENSE (INCLUDING ATTORNEYS FEES) OF ANY KIND OR NATURE, WHETHER SPECIAL, CONSEQUENTIAL, ECONOMIC OR OTHERWISE, CAUSED OR ALLEGED TO BE CAUSED DIRECTLY, INDIRECTLY, INCIDENTALLY, OR CONSEQUENTIALLY BY THE ASSETS OR ANY PART THEREOF OR PRODUCTS THEREFROM, BY ANY INADEQUACY OF THE ASSETS OR DEFECT OR DEFICIENCY THEREIN, BY ANY INCIDENT WHATSOEVER ARISING IN STRICT LIABILITY OR OTHERWISE FROM SELLER'S OR BUYER'S NEGLIGENCE OR OTHERWISE, OR FOR ANY LOSS OF BUSINESS OR DAMAGE WHATSOEVER AND HOWSOEVER CAUSED, OR ARISING OUT THE ASSETS.

Buyer acknowledges that Seller has made no representation or warranty concerning the location of the Assets nor whether all of the Assets are in existence or operational. BUYER PURCHASES THE ASSETS "AS IS" AND WHERESOEVER LOCATED, WITHOUT REPRESENTATION OR WARRANTY OF ANY KIND. Buyer accepts the Assets subject to the terms of this Bill of Sale, and subject to the terms, conditions, and warranties contained in the Purchase Agreement.

Buyer agrees to be responsible for all taxes, that are now existing or hereafter are incurred, assessed, or imposed on the Assets or as a result of the ownership or sale of the Assets. Buyer hereby agrees to hold Seller harmless from and against any and all taxes that are now existing or are hereafter incurred, assessed or imposed on the Assets or as a result of the ownership of the Assets.

SELLER:

SILICON VALLEY BANK, a State BODY SYNC, INC., a Nevada corporation Chartered Bank
Pursuant to § 9-617
For itself and for and on behalf of Sciona, Inc. a Delaware corporation

By:

By:

Title:

101346

Name: Title:

SELLER SHALL HAVE NO LIABILITY TO BUYER OR ANY PERSON WHOMSOEVER (INCLUDING LESSEES OR PURCHASERS OF ALL OR ANY OF THE ASSETS) FOR ANY CLAIM, LOSS, DAMAGE OR EXPENSE (INCLUDING ATTORNEYS FEES) OF ANY KIND OR NATURE, WHETHER SPECIAL, CONSEQUENTIAL, ECONOMIC OR OTHERWISE, CAUSED OR ALLEGED TO BE CAUSED DIRECTLY, INDIRECTLY, INCIDENTALLY, OR CONSEQUENTIALLY BY THE ASSETS OR ANY PART THEREOF OR PRODUCTS THEREFROM, BY ANY INADEQUACY OF THE ASSETS OR DEFECT OR DEFICIENCY THEREIN, BY ANY INCIDENT WHATSOEVER ARISING IN STRICT LIABILITY OR OTHERWISE FROM SELLER'S OR BUYER'S NEGLIGENCE OR OTHERWISE, OR FOR ANY LOSS OF BUSINESS OR DAMAGE WHATSOEVER AND HOWSOEVER CAUSED, OR ARISING OUT THE ASSETS.

Buyer acknowledges that Seller has made no representation or warranty concerning the location of the Assets nor whether all of the Assets are in existence or operational. BUYER PURCHASES THE ASSETS "AS IS" AND WHERESOEVER LOCATED, WITHOUT REPRESENTATION OR WARRANTY OF ANY KIND. Buyer accepts the Assets subject to the terms of this Bill of Sale, and subject to the terms, conditions, and warranties contained in the Purchase Agreement.

Buyer agrees to be responsible for all taxes, that are now existing or hereafter are incurred, assessed, or imposed on the Assets or as a result of the ownership or sale of the Assets. Buyer hereby agrees to hold Seller harmless from and against any and all taxes that are now existing or are hereafter incurred, assessed or imposed on the Assets or as a result of the ownership of the Assets.

SEI	ĭ	FR.

BUYER:

SILICON VALLEY BANK, in State Chartered Bank
Pursuant to § 9-617
For itself and for and on behalf of Sciona, Inc. a Delaware corporation

SYNTHESIS MARKETING & COMMUNICATIONS, INC., a California corporation

	•
By: Name: Tide:	
Tome:	
Name.	
Title:	

By Patricia Ellemedia Names Patricia Ellennedia Title: President

ASSIGNMENT AND ASSUMPTION AGREEMENT

By this Assignment and Assumption Agreement ("Agreement") Synthesis Marketing & Communications, Inc., a California Corporation ("Synthesis"), hereby transfers and assigns to Body Sync, Inc., a Nevada Corporation ("BodySync"), all of Synthesis' rights, title and interest related to and arising from the Secured Creditor Asset Purchase Agreement, dated August 31, 2009, by and between Synthesis, as purchaser, and Silicon Valley Bank, a state chartered bank, as seller (the "Asset Purchase Agreement").

BodySync hereby assumes all obligations and liabilities of Synthesis under the Asset Purchase Agreement.

Dated: September 18, 2009

SYNTHESIS MARKETING & COMMUNICATIONS, INC.

Patricia Kennedy

Its: President

BODY SYNC, INC.

Vince Paveloc

Its: President

By:

RECORDED: 03/05/2010